These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 25515960)

  • 1. The role of the Janus-faced transcription factor PAX5-JAK2 in acute lymphoblastic leukemia.
    Schinnerl D; Fortschegger K; Kauer M; Marchante JR; Kofler R; Den Boer ML; Strehl S
    Blood; 2015 Feb; 125(8):1282-91. PubMed ID: 25515960
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PAX5-ELN oncoprotein promotes multistep B-cell acute lymphoblastic leukemia in mice.
    Jamrog L; Chemin G; Fregona V; Coster L; Pasquet M; Oudinet C; Rouquié N; Prade N; Lagarde S; Cresson C; Hébrard S; Nguyen Huu NS; Bousquet M; Quelen C; Brousset P; Mancini SJC; Delabesse E; Khamlichi AA; Gerby B; Broccardo C
    Proc Natl Acad Sci U S A; 2018 Oct; 115(41):10357-10362. PubMed ID: 30257940
    [No Abstract]   [Full Text] [Related]  

  • 3. PAX5/TEL acts as a transcriptional repressor causing down-modulation of CD19, enhances migration to CXCL12, and confers survival advantage in pre-BI cells.
    Fazio G; Palmi C; Rolink A; Biondi A; Cazzaniga G
    Cancer Res; 2008 Jan; 68(1):181-9. PubMed ID: 18172310
    [TBL] [Abstract][Full Text] [Related]  

  • 4. EBF1-JAK2 inhibits the PAX5 function through physical interaction with PAX5 and kinase activity.
    Kojima Y; Kawashima F; Yasuda T; Odaira K; Inagaki Y; Yamada C; Muraki A; Noura M; Okamoto S; Tamura S; Iwamoto E; Sanada M; Matsumura I; Miyazaki Y; Kojima T; Kiyoi H; Tsuzuki S; Hayakawa F
    Int J Hematol; 2023 Jul; 118(1):65-74. PubMed ID: 37149540
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ph-like acute lymphoblastic leukemia with a novel PAX5-KIDINS220 fusion transcript.
    Sakamoto K; Imamura T; Kanayama T; Yano M; Asai D; Deguchi T; Hashii Y; Tanizawa A; Ohshima Y; Kiyokawa N; Horibe K; Sato A
    Genes Chromosomes Cancer; 2017 Apr; 56(4):278-284. PubMed ID: 27870151
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The PAX5-JAK2 translocation acts as dual-hit mutation that promotes aggressive B-cell leukemia via nuclear STAT5 activation.
    Jurado S; Fedl AS; Jaritz M; Kostanova-Poliakova D; Malin SG; Mullighan CG; Strehl S; Fischer M; Busslinger M
    EMBO J; 2022 Apr; 41(7):e108397. PubMed ID: 35156727
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incidence and diversity of PAX5 fusion genes in childhood acute lymphoblastic leukemia.
    Nebral K; Denk D; Attarbaschi A; König M; Mann G; Haas OA; Strehl S
    Leukemia; 2009 Jan; 23(1):134-43. PubMed ID: 19020546
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of RUNX1-JAK2 in Human Induced Pluripotent Stem Cell-Derived Hematopoietic Cells Activates the JAK-STAT and MYC Pathways.
    Fortschegger K; Husa AM; Schinnerl D; Nebral K; Strehl S
    Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299194
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The reduced and altered activities of PAX5 are linked to the protein-protein interaction motif (coiled-coil domain) of the PAX5-PML fusion protein in t(9;15)-associated acute lymphocytic leukemia.
    Qiu JJ; Chu H; Lu X; Jiang X; Dong S
    Oncogene; 2011 Feb; 30(8):967-77. PubMed ID: 20972455
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Functional heterogeneity of PAX5 chimeras reveals insight for leukemia development.
    Fortschegger K; Anderl S; Denk D; Strehl S
    Mol Cancer Res; 2014 Apr; 12(4):595-606. PubMed ID: 24435167
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Functional analysis of a novel fusion protein PAX5-KIDINS220 identified in a pediatric Ph-like ALL patient.
    Kanayama T; Imamura T; Mayumi A; Soma E; Sakamoto K; Hayakawa F; Tanizawa A; Kiyokawa N; Hosoi H
    Int J Hematol; 2020 Nov; 112(5):714-719. PubMed ID: 32656633
    [TBL] [Abstract][Full Text] [Related]  

  • 12. B Cell Linker Protein (BLNK) Is a Selective Target of Repression by PAX5-PML Protein in the Differentiation Block That Leads to the Development of Acute Lymphoblastic Leukemia.
    Imoto N; Hayakawa F; Kurahashi S; Morishita T; Kojima Y; Yasuda T; Sugimoto K; Tsuzuki S; Naoe T; Kiyoi H
    J Biol Chem; 2016 Feb; 291(9):4723-31. PubMed ID: 26703467
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PAX5 is part of a functional transcription factor network targeted in lymphoid leukemia.
    Okuyama K; Strid T; Kuruvilla J; Somasundaram R; Cristobal S; Smith E; Prasad M; Fioretos T; Lilljebjörn H; Soneji S; Lang S; Ungerbäck J; Sigvardsson M
    PLoS Genet; 2019 Aug; 15(8):e1008280. PubMed ID: 31381561
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transforming and tumorigenic activity of JAK2 by fusion to BCR: molecular mechanisms of action of a novel BCR-JAK2 tyrosine-kinase.
    Cuesta-Domínguez Á; Ortega M; Ormazábal C; Santos-Roncero M; Galán-Díez M; Steegmann JL; Figuera Á; Arranz E; Vizmanos JL; Bueren JA; Río P; Fernández-Ruiz E
    PLoS One; 2012; 7(2):e32451. PubMed ID: 22384256
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chromosomal translocation-mediated evasion from miRNA induces strong MEF2D fusion protein expression, causing inhibition of PAX5 transcriptional activity.
    Hirano D; Hayakawa F; Yasuda T; Tange N; Yamamoto H; Kojima Y; Morishita T; Imoto N; Tsuzuki S; Mano H; Naoe T; Kiyoi H
    Oncogene; 2019 Mar; 38(13):2263-2274. PubMed ID: 30478446
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative genomics reveals multistep pathogenesis of E2A-PBX1 acute lymphoblastic leukemia.
    Duque-Afonso J; Feng J; Scherer F; Lin CH; Wong SH; Wang Z; Iwasaki M; Cleary ML
    J Clin Invest; 2015 Sep; 125(9):3667-80. PubMed ID: 26301816
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of PML as novel PAX5 fusion partner in childhood acute lymphoblastic leukaemia.
    Nebral K; König M; Harder L; Siebert R; Haas OA; Strehl S
    Br J Haematol; 2007 Oct; 139(2):269-74. PubMed ID: 17897302
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dominant-negative mechanism of leukemogenic PAX5 fusions.
    Kawamata N; Pennella MA; Woo JL; Berk AJ; Koeffler HP
    Oncogene; 2012 Feb; 31(8):966-77. PubMed ID: 21765475
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EBF1 and Pax5 safeguard leukemic transformation by limiting IL-7 signaling, Myc expression, and folate metabolism.
    Ramamoorthy S; Kometani K; Herman JS; Bayer M; Boller S; Edwards-Hicks J; Ramachandran H; Li R; Klein-Geltink R; Pearce EL; Grün D; Grosschedl R
    Genes Dev; 2020 Nov; 34(21-22):1503-1519. PubMed ID: 33004416
    [No Abstract]   [Full Text] [Related]  

  • 20. Activating PAX gene family paralogs to complement PAX5 leukemia driver mutations.
    Hart MR; Anderson DJ; Porter CC; Neff T; Levin M; Horwitz MS
    PLoS Genet; 2018 Sep; 14(9):e1007642. PubMed ID: 30216339
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.